You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: BioIncept, LLC Topic: NICHD
ABSTRACT Perinatal hypoxic ischemic encephalopathy HIE affects to infants per every born Mortality from HIE can be up to and approximately of survivors suffer significant long term disability including cerebral palsy epilepsy and developmental disorders Damage during the acute phase of HIE is caused by a deficit in oxygen and glucose in the brain However increasing evide ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: AFASCI, INC. Topic: NIDA
DESCRIPTION provided by applicant The abuse of illicit drugs such as cocaine marijuana and heroin remains a critical public health concern throughout the country and is associated with staggering economic and social consequences Cocaine remains the most frequently recorded illicit drug in emergency hospital visits and the leading cause of drug related deaths in the United States Since as hi ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: ENSION Inc Topic: NHLBI
Abstract This Phase I STTR application proposes development of an innovative low cost magnetic levitation motor specifically designed for pediatric extracorporeal cardiac and cardiopulmonary therapies Magnetic levitation enables contact free impeller operation thereby eliminating critical areas of wear and heat generation that can contribute to hemolysis and thrombosis The extracorporeal pedia ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NHLBI
DESCRIPTION provided by applicant We have discovered the first ever inhibitors of PF a platelet protein central to the pathophysiology of heparin induced thrombocytopenia HIT Heparin is a naturally occurring anticoagulant that prevents the formation of clots and extension of existing clots within the vasculature and major medical applications of heparin include dialysis cardiac catheteri ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Novici Biotech LLC Topic: NHLBI
DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: ARISAN THERAPEUTICS INC Topic: NIAID
Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great impor ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Development of a Genotype-linked Antibiotic Resistance Platform for Real Time Pathogen Risk Classification and EpidemiologySBC: MAVERIX BIOMICS, INC. Topic: NIAID
Project Summary Antibiotic resistance has become a pressing public health concern due to the rise of pathogenic bacterial strains with mutations that reduce or eliminate the effectiveness of drugs to treat infections Beta lactamases produced by some bacteria provide resistance by degrading beta lactams one of most widely used class of antibiotics Originally restricted to penicillins mutant bet ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Blockade of histamine-releasing factor as a new prophylactic and therapeutic strategy for food allergySBC: ABWIZ BIO INC Topic: NIAID
DESCRIPTION provided by applicant The prevalence of food allergy has been dramatically increasing for the last few decades Food Allergy and Anaphylaxis Network www foodallergy org estimates that up to million Americans have food allergies Six to eight percent of children under the age of three have food allergies and nearly four percent of adults have them Signs and symptoms of food all ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: SEACOAST SCIENCE, INC. Topic: NIEHS
Project Summary This Small Business Technology Transfer Phase I project proposes the development and optimization of a commercially viable novel polymer based radiation dosimeter for wide spread deployment The radiation dosimeter proposed herein is a disruptive technology with a significant market Although many commercial radiation dosimeters measure individual radiation load dose quantificatio ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: EUNOIA BIOTECH LLC Topic: 400
Title Simvastatin nanomedicine in ARDS and sepsis The host response to severe infection termed sepsis affects more than million Americans yr generating annual direct costs exceeding $ billion Novel therapies are sorely needed to target maladaptive features of the host response that complement antimicrobial drugs and advances in supportive care Microcirculatory hyperpermeability may be a ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health